

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE ANY OTHER MEASURES THAN REQUIRED BY SWEDISH LAW.

Tomorrow, the subscription period in Coala-Life's rights issue, begins. Subscription undertakings and guarantee commitments amounts to approx. 76.5% of the issue, corresponding to approx. SEK 77.6M.

Tomorrow, February 7, 2023, the subscription period in Coala-Life Group AB's (publ) ("Coala Life" or the "Company") rights issue of units of up to approximately SEK 101 million (the "Rights Issue") which was proposed by the Company's Board of Directors on December 23, 2022, and resolved at an Extraordinary General Meeting on January 26, 2023, commences. The Rights Issue is covered by subscription undertakings and guarantee commitments from existing shareholders and new investors of approximately SEK 77.6 million, corresponding to approximately 76.5 percent of the Rights Issue, which is slightly more than previously announced.

Coala Life carries out a Rights Issue of units consisting of one (1) share and one (1) warrant of series TO 1, issued free of charge. Upon full subscription, the Company will initially receive proceeds of approximately SEK 101 million before deduction of transaction costs. The initial issue proceeds are covered by subscription undertakings and guarantee commitments from existing shareholders and new investors corresponding to approximately 76.5 percent of the Rights Issue, which is an increase since the Rights Issue was announced on December 23, 2022. Subscription undertakings and guarantee commitments was at that time announced to be approximately 75 percent of the Rights Issue. Upon full subscription of the Rights Issue and subsequent exercise of all warrants issued, the Company may additionally receive approximately SEK 16.6 million to SEK 46.4 million before deduction of transaction costs.

For each share held in Coala Life on the record date 2 February 2023, shareholders will receive five (5) unit rights. Two (2) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of one (1) new share and one (1) warrant issued free of charge. The subscription price is SEK 0.51 per unit, which refers to the share. The warrants are issued without consideration. Three (3) warrants of series TO 1 entitle the holder to subscribe for one (1) new share in the Company during the period September 11, 2023 – September 22, 2023 at a subscription price per share corresponding to seventy (70) percent of the volume weighted average trading price (WVAP) of the Company's share on Nasdaq First North Growth Market, during a period of ten (10) trading days prior to and including, 8 September, 2023, but no less than SEK 0.25 and no more than SEK 0.7 per share.

Subscription period:	7 February – 21 February, 2023
Trading in unit rights:	7 February – 16 February, 2023
Trading in BTU´s:	February 7, 2023, until the Rights Issue is registered with the Swedish Companies Registration Office
Trading in warrants of series TO 1:	Will be initiated when the Rights Issue is registered with the Swedish Companies Registration Office

The outcome of the Rights Issue is expected to be announced on or around 22 February 2023.

Prospectus

Full terms and conditions for the Rights Issue, as well as more detailed information about the net proceeds, guarantee commitments etc. will be included in the EU growth prospectus that will be published later today ("**the Prospectus**"). The Prospectus will be available on the respective websites of Coala Life, Redeye, and Nordic Issuing AB (www. coalalife.com, www.redeye.se, www.nordic-issuing.se) as well as in the Prospectus register administered by the Swedish Financial Supervisory Authority (www.fi.se/en/).

Advisers

Redeye AB acts as financial adviser and Setterwalls Advokatbyrå AB acts as legal adviser in connection with the Rights Issue. Nordic Issuing acts as the issuing agent in the Rights Issue. Issue.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in the Company. No action has been taken and no measures will be taken to permit a public offering in any jurisdictions other than Sweden.

This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify, or purport to identify, risks (direct or indirect) that may be associated with an investment in shares or other securities in the Company. A so-called EU Growth Prospectus (the "**Prospectus**") will be prepared in connection with the Rights Issue and be reviewed and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) which is the national competent authority in Sweden under the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. This press release constitutes an advertisement in accordance with article 2 k of the Prospectus Regulation.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Russia, Switzerland, Singapore, South Africa or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in the Company have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act ") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area ("**EEA**"), no public offering of shares or other securities ("**Securities**") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under a not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this press release relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about the Company's future results, financial condition, liquidity, development, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should",

"could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdag First North Growth Market's rule book for issuers.

About us

Coala-Life Group AB ("Coala Life" or the "Company") founded in 2015, is a Cloud Based Software as a Service provider, and medical device developer and reseller, listed on Nasdaq First North Growth Market. The Company focuses on B2B solutions for managed Remote Patient Monitoring ("RPM"), offering medical care providers, primarily in the US, with a highly scalable, cost-efficient platform to remotely and virtually manage large volumes of patients suffering from chronic diseases. The company offers care providers a comprehensive solution and lifts the administrative work from the care providers regarding, amongst other things, follow-up, 24/7 monitoring, as well as the reimbursement process from state and private health insurance companies. Patients are monitored long-term in everyday life and typically have diabetes, obesity, and /or cardiovascular disease.

For more information see www.coalalife.com

For more information, please contact:

Dan Pitulia, CEO Coala Life AB +46 70 972 08 38, **dan.pitulia@coalalife.com** Richard Roa, CFO Coala Life AB +46 70 816 61 45, **richard.roa@coalalife.com**

Certified Adviser The company's Certified Adviser is Erik Penser Bank AB.

Attachments

Tomorrow, the subscription period in Coala-Life's rights issue, begins. Subscription undertakings and guarantee commitments amounts to approx. 76.5% of the issue, corresponding to approx. SEK 77.6M.